Brad Marion
Pulmonary Disease · Oklahoma City, OKNPI 1679644348
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.0% of the total across 142 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by AstraZeneca at 30.2% of the total. Reporting peaked in 2022 at $1,287 and has fallen 97.6% since, to $31 in 2023. That places this record below the midpoint for pulmonary disease clinicians in OK, where the typical reported total is $1,778.
Across 142 payments — averaging $17.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$740
- GSK$339
- Takeda Pharmaceuticals U.S.A., Inc.$223
- Boehringer Ingelheim$177
- Sunovion Pharmaceuticals Inc.$161
- Baxter Healthcare$145
- plus $664 from 16 others
What the payments were for
- Food & beverage$2,39998%
- Education$482%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 30 | $740 |
| GSK | 28 | $339 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $223 |
| Boehringer Ingelheim | 10 | $177 |
| Sunovion Pharmaceuticals Inc. | 15 | $161 |
| Baxter Healthcare | 8 | $145 |
| Actelion Pharmaceuticals US, Inc. | 8 | $135 |
| Novartis | 5 | $79 |
| Mylan Specialty L.p. | 4 | $62 |
| Grifols USA, LLC | 2 | $40 |
| Sanofi | 2 | $40 |
| Shire North American Group Inc | 2 | $38 |
| CSL Behring | 2 | $37 |
| Regeneron Healthcare Solutions, Inc. | 2 | $37 |
| Inogen, Inc. | 4 | $35 |
| Insmed, Inc. | 2 | $32 |
| AbbVie | 1 | $31 |
| Optinose US, Inc. | 2 | $31 |
| Melinta Therapeutics, LLC | 1 | $19 |
| Gilead | 1 | $18 |
| Amgen | 1 | $15 |
| Advanced Respiratory, Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,448 in reported general payments places this provider in the 50th percentile of 133 pulmonary disease providers in Oklahoma.
Other pulmonary disease in Oklahoma City
- John KingreyOklahoma City$332K
- Fawad ChaudryOklahoma City$80K
- Maroun TawkOklahoma City$62K
- Nathaniel MoultonOklahoma City$28K
- Syed NaqviOklahoma City$15K
- Tarek DernaikaOklahoma City$12K
- Shoab NazirOklahoma City$11K
- Mark GodishOklahoma City$11K
- Mazen ZouwayhedOklahoma City$10K
- Shoaib AhmadOklahoma City$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.